Merck's Keytruda Conditionally Approved In Canada For Triple-Negative Breast Cancer

Health Canada has conditionally approved Merck & Co Inc's MRK Keytruda (pembrolizumab) for a form of breast cancer.
The approval covers adult patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 and who have not received prior chemotherapy for metastatic disease.
The conditional approval is based on Phase 3 KEYNOTE-355 trial results. Keytruda demonstrated improved progression-free survival (PFS) in combination with chemotherapy compared to chemotherapy alone.
Related Link: Merck Backs Up Keytruda Approval In TNBC With Encouraging Overall Survival Data.
Price Action: MRK shares are up 1.37% at $82.76 during the market session on the last check Tuesday.

Posted In:

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.